VERA PRISACARI: Open Payments
NPI 1982196564 · EDINA, MN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$778 in 36 payments from 11 companies in 2025. Trend: 2023 $150 · 2024 $415 · 2025 $778
Food & beverage: $778
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 6 | $185 |
| ABBVIE INC. | 8 | $139 |
| Neurocrine BioSciences, Inc. | 3 | $87 |
| Supernus Pharmaceuticals, Inc. | 4 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| Vanda Pharmaceuticals Inc. | 2 | $57 |
| E.R. Squibb & Sons, L.L.C. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Lundbeck LLC | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
Products named: Auvelity, VRAYLAR, INGREZZA, REXULTI, Qelbree, AUSTEDO XR, FANAPT, COBENFY.
Industry payments across MN — which companies pay providers there.
